Intellia Therapeutics and ReCode Therapeutics are joining forces to develop new genomic medicines for people with cystic fibrosis (CF). The companies said initial research will focus on patients who have “limited or no treatment options available.” The ultimate goal is to create a new genomic medicine that…
News
Certain markers of inflammation found deep in the lungs of children with cystic fibrosis (CF) can help predict how bronchiectasis will worsen over time, offering insights for better treatment and care, a study suggests. Among other markers, higher levels of interleukin-8 (IL-8), a signaling…
Between 2011 and 2021, improving lung function and better survival rates were consistently seen among people with cystic fibrosis (CF) in Europe, particularly in wealthier countries and with the introduction of new treatments, according to a study that tracked more than 45,000 CF patients across the continent over the…
The antibiotic arenicin may be effective at killing resistant Mycobacterium abscessus, a type of bacteria that can cause serious infections in people with cystic fibrosis (CF), according to a study in cells. Given alone or in combination with conventional antibiotics,…
A greater increase in body mass index (BMI), a measure of body fat, from ages 1 through 6 in boys with cystic fibrosis (CF) results in the early production of sex hormones, called adrenarche, according to a small study. Boys with early adrenarche had…
Up to almost 30% of teenagers and adults with cystic fibrosis (CF) in the U.S. have smoked marijuana and/or cannabidiol (CBD), one of the active components of cannabis, according to an online survey. Use of e-cigarettes and traditional cigarettes was just as common among them.
The frequent use of aminoglycosides — a class of antibiotics commonly used to help treat lung infections in people with cystic fibrosis (CF) — has been linked to an increased risk of hearing problems in CF patients, starting in childhood, according to a new pediatric study in Belgium. The…
A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor — outperformed the approved therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) at reducing sweat chloride levels in Phase 3 trials. The new “vanza triple” combo was similar to Trikafta at maintaining…
An eight-week remote exercise program of moderate to high intensity increased leg muscle strength and reduced body fat in adults with cystic fibrosis (CF), a new study showed. While no differences were found in lung function and quality of life, the gains seen with the short-term duration of the exercise…
A pooled analysis of data from multiple clinical trials of more than 1,100 people with cystic fibrosis (CF) confirms Trikafta effectively improves lung function, sweat chloride levels, and health-related quality of life. “Further monitoring and assessment of the safety profile of [Trikafta]…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.